Ranibizumab for treating choroidal neovascularisation associated with pathological myopia

  • Technology appraisal guidance
  • TA298
  • Published: 

Review decision – October 2016

Decision to move the existing guidance to the static list

The Institute was proposing that TA298 should be moved to the static list.

After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.

Consequently, TA298 will be moved to the static list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

Review decision paper

This page was last updated: